BRAF and NRAS gene mutations are common in NAM; however, only 15.5% of AM carries a BRAF gene mutation, and therefore the majority of AM patients do not benefit from targeted therapies2. The gene discussed is NRAS; the disease is acute myeloblastic leukemia with maturation.